Showing results (461-470 of 478) with videos related to
Sort By:
Pageof 48
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|August 9, 2020
Impact of COVID-19 pandemic on STEMI care: An expanded analysis from the United StatesSantiago Garcia, Larissa Stanberry, Christian Schmidt, et al.Journal of the American College of Cardiology|September 13, 2023
Comprehensive Management of ANOCA, Part 2-Program Development, Treatment, and Research Initiatives: JACC State-of-the-Art ReviewNathaniel R Smilowitz, Megha Prasad, R Jay Widmer, et al.Texas Heart Institute Journal|September 17, 2010
LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarctionJay H Traverse, Timothy D Henry, Douglas E Vaughan, et al.American Heart Journal|August 25, 2009
Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarctionJay H Traverse, Timothy D Henry, Douglas E Vaughan, et al.Circulation Research|August 20, 2014
Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomesChristopher R Cogle, Elizabeth Wise, Amy M Meacham, et al.Journal of the American College of Cardiology|September 13, 2023
Comprehensive Management of ANOCA, Part 1-Definition, Patient Population, and Diagnosis: JACC State-of-the-Art ReviewBruce A Samuels, Samit M Shah, R Jay Widmer, et al.Circulation Research|February 21, 2015
Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient dataMariann Gyöngyösi, Wojciech Wojakowski, Patricia Lemarchand, et al.The New England Journal of Medicine|November 18, 2024
Routine Spironolactone in Acute Myocardial InfarctionSanjit S Jolly, Marc-André d'Entremont, Bertram Pitt, et al.JACC. Cardiooncology|January 6, 2021
Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients: The CCTRN SENECA TrialRoberto Bolli, Emerson C Perin, James T Willerson, et al.European Journal of Heart Failure|April 3, 2021
A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trialRoberto Bolli, Raul D Mitrani, Joshua M Hare, et al.Pageof 48